GEMOX方案动静脉两种不同给药途径治疗晚期胰腺癌的效果比较  

The effect comparison of GEMOX program by artery and veins two different routes of administration on the patients with advanced pancreatic cancer

作　　者：颜廷华[1] 谷文龙[1] 俞进友[1] 赵明宏[1] 孙军[1] 赵晓航[2] 

机构地区：[1]江苏省盐城市建湖县人民医院肿瘤中心,江苏建湖224700 [2]中国医学科学院肿瘤研究所,北京100021

出　　处：《中国医药导报》2013年第36期83-85,共3页China Medical Herald

基　　金：国家自然科学基金项目(编号30973373)

摘　　要：目的探讨GEMOX方案动静脉两种不同给药途径治疗晚期胰腺癌的效果及安全性,为临床合理用药提供有效的依据。方法将2008年3月～2012年6月江苏省盐城市建湖县人民医院确诊为晚期胰腺癌的49例患者分为两组:动脉组22例和静脉组27例,采用GEMOX方案经动静脉两种不同途径化疗2个周期后,比较两组患者的临床疗效、临床受益反应及不良反应。结果动脉组有效率为36.4%,获益率为68.2%,疾病无进展时间为5.2个月,1年生存率为45.5%,临床受益反应率为63.6%。静脉组有效率为25.9%,获益率为44.4%,疾病进展时间为4.7个月,1年生存率为18.5%,临床受益反应率为33.3%。动脉组在获益率、1年生存率、临床受益反应率方面显著高于静脉组(P<0.05),而两组的近期有效率、疾病无进展时间及不良反应方面差异无统计学意义(P>0.05)。两组主要不良反应为血液学、胃肠道、外周神经毒性反应,组间比较差异无统计学意义(P>0.05)。结论与GEMOX方案全身静脉化疗相比,GEMOX方案动脉介入给药治疗晚期胰腺癌可有较好的近期临床疗效,可显著提高患者临床获益率、1年生存率及患者的生活质量。Objective To explore the effect and the security of GEMOX program by artery and veins two different routes of administration on the patients of advanced pancreatic cancer. Methods 49 cases of patients with advanced pancreatic cancer in the People＇s Hospital of Jianhu County in Yanchang City of Jiangsu Province from March 2008 to June 2012 were divided into two groups. Arterial infusion chemotherapy group had 22 cases,while the intravenous chemotherapy group had 27 cases. Clinical efficacy,clinical benefit response and side-reactions were compared between the two groups after 2 cycles of GEMOX program by arterg and veins two different routes of administration. Results In the arterial infusion chemotherapy group,the effective rate was 36.4%,the benefit rate was 68.2%,time to progression was 5.2 months,1-year survival rate was 45.5%,the clinical benefit response rate was 63.6%. In the intravenous chemotherapy group,the effective rate was 25.9%,the benefit rate was 44.4%,time to progression was 4.7 months,1-year survival rate was 18.5%,the clinical benefit response rate was 33.3%. The benefit rate,1-year survival,clinical benefit response rate of the arterial infusion chemotherapy group were significantly higher than those in the intravenous chemotherapy group（P〈 0.05）,and the recent efficiency,disease progression time and adverse reactions showed no significant differences（P〉 0.05）. The main side-reactions were hematology,gastrointestinal tract,peripheral nerve toxicity,the difference between the two groups was not statistically significant（P 0.05）. Conclusion GEMOX program artery interventional treatment have a better short-term clinical efficacy compared with the arterial infusion chemotherapy. It can significantly improve the clinical benefit rate,1-year survival and quality of life of patients.

关 键 词：晚期胰腺癌 吉西他滨 奥沙利铂 化疗 动脉介入 

分 类 号：R735.905[医药卫生—肿瘤]